Publications by authors named "F Lerebours"
Background: Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer in SOLAR-1; limited data are available in the post-cyclin-dependent kinase 4/6 inhibitor setting. BYLieve aimed to assess alpelisib plus endocrine therapy in this setting in three cohorts defined by immediate previous treatment; here, we report results from cohort A.
Methods: This ongoing, phase 2, multicentre, open-label, non-comparative study enrolled patients with hormone receptor-positive, HER2-negative, advanced breast cancer with tumour PIK3CA mutation, following progression on or after previous therapy, including CDK4/6 inhibitors, from 114 study locations (cancer centres, medical centres, university hospitals, and hospitals) in 18 countries worldwide.
Article Synopsis
- Patients with high-risk hormone receptor-positive, HER2-negative breast cancer (HR+ BC) show a significant risk of relapse, prompting the need for additional treatment strategies.
- The study analyzed data from the CANcer TOxicities (CANTO) study, involving patients between 2012 and 2022, categorizing them based on various unfavorable features indicating high risk.
- Results indicated that most patients underwent (neo)adjuvant chemotherapy and endocrine therapy; however, many discontinued treatment due to adverse events, with a 5-year survival rate reflecting the need for ongoing management in this patient group.
Article Synopsis
- The study explores the link between migraine with aura (MWA) and cerebral small-vessel disease (CSVD) in young adults who experienced their first ischemic stroke.
- Out of 646 patients, those with MWA showed a lower frequency of potentially causal CSVD lesions compared to non-migraine patients, but this disappeared after adjusting for vascular risk factors.
- The findings suggest that MWA may not have a significant association with CSVD as a cause of stroke in this population.
Background: Neoadjuvant chemotherapy (NACT) became a standard treatment strategy for patients with inflammatory breast cancer (IBC) because of high disease aggressiveness. However, given the heterogeneity of IBC, no molecular feature reliably predicts the response to chemotherapy. Whole-exome sequencing (WES) of clinical tumor samples provides an opportunity to identify genomic alterations associated with chemosensitivity.
View Article and Find Full Text PDFArticle Synopsis
- This study evaluated how certain biomarkers from pretreatment PET/CT scans relate to patient outcomes in those with metastatic breast cancer (mBC) receiving specific antibody-drug conjugates (ADCs) - Sacituzumab Govitecan (SG) and Trastuzumab Deruxtecan (T-DXd).
- Conducted on 128 patients, the research found that higher levels of total metabolic tumor volume (TMTV) and maximum tumor dissemination (Dmax) were linked to shorter overall survival (OS) and progression-free survival (PFS) in both treatment groups.
- The conclusion highlights the potential of these biomarkers for improving survival predictions and tailoring treatment plans for mTNBC and